IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) and Pfenex Inc. (NYSEAMERICAN:PFNX), both competing one another are Biotechnology companies. We will compare their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IntelliPharmaCeutics International Inc.	N/A	0.00	N/A	-3.26	0.00
Pfenex Inc.	14.86M	12.72	39.59M	-0.99	0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 represents IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) and Pfenex Inc. (NYSEAMERICAN:PFNX)’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IntelliPharmaCeutics International Inc.	0.00%	0%	0%
Pfenex Inc.	-266.42%	-43.7%	-32.3%

Volatility & Risk

IntelliPharmaCeutics International Inc.’s 2.19 beta indicates that its volatility is 119.00% more volatile than that of S&P 500. From a competition point of view, Pfenex Inc. has a 2.78 beta which is 178.00% more volatile compared to S&P 500.

Insider & Institutional Ownership

The shares of both IntelliPharmaCeutics International Inc. and Pfenex Inc. are owned by institutional investors at 0.5% and 81.6% respectively. Insiders owned roughly 56.5% of IntelliPharmaCeutics International Inc.’s shares. On the other hand, insiders owned about 0.1% of Pfenex Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
IntelliPharmaCeutics International Inc.	-15.57%	-12.12%	-18.42%	-87.94%	-95.32%	19.88%
Pfenex Inc.	14.08%	19.29%	17.79%	-11.15%	22.72%	47.34%

For the past year IntelliPharmaCeutics International Inc.’s stock price has smaller growth than Pfenex Inc.

Summary

On 5 of the 9 factors Pfenex Inc. beats IntelliPharmaCeutics International Inc.

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The companyÂ’s lead product is Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for attention deficit hyperactivity disorders. It also develops Rexista Oxycodone, an abuse and alcohol-deterrent controlled-release oral formulation for the relief of pain; Regabatin XR and Lyrica pregabalin extended-release capsules for the management of neuropathic pain; Effexor XR, an extended-release capsule for oral administration to treat depression; and Protonix, a delayed-release capsule for oral administration to treat gastroesophageal reflux disease. In addition, the company offers Glucophage XR, an oral antihyperglycemia drug to treat type 2 diabetes; Seroquel XR, an oral psychotropic agent for the treatment of schizophrenia, bipolar disorder, and major depressive disorder; Lamictal XR, an anticonvulsant drug to terat epilepsy; Keppra XR, an antiepileptic drug for the treatment of partial onset seizures in patients with epilepsy; and Pristiq, a selective serotonin and norepinephrine reuptake inhibitor to treat major depressive disorder. Further, it provides Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Ranexa, a ranolazine extended release tablet for chronic angina. Intellipharmaceutics International Inc. has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.

Pfenex Inc., a clinical-stage biotechnology company, develops biosimilar therapeutics in the United States. Its lead product candidates include PF708, a therapeutic equivalent candidate to Forteo (teriparatide) for the treatment of osteoporosis; PF582, a biosimilar to Lucentis (ranibizumab) for the treatment of patients with retinal diseases; and Px563L, a novel anthrax vaccine candidate in Phase 1a trial. The company also engages in developing a pipeline of additional biosimilar candidates, including PF529, a biosimilar candidate to Neulasta; PF688, a biosimilar candidate to Cimzia; PF530, a biosimilar candidate to Betaseron; PF690, a biosimilar candidate to the reference product Oncaspar; PF444-human growth hormone, a biosimilar candidate to Genotropin; and PF688-certolizumab-pegol, a biosimilar candidate to Cimzia. It has collaboration agreements with Hospira, Inc. and Jazz Pharmaceuticals Ireland Limited. Pfenex Inc. is headquartered in San Diego, California.